24
Breast Adipose Inflammation: a Silent Killer ANDREW J. DANNENBERG, M.D. November 17, 2017

Breast Adipose Inflammation: a Silent Killer · Silent Killer ANDREW J. DANNENBERG, M.D. November 17, 2017. Obesity and Breast Cancer • Risk factor for development of hormone receptor-

  • Upload
    others

  • View
    0

  • Download
    0

Embed Size (px)

Citation preview

Page 1: Breast Adipose Inflammation: a Silent Killer · Silent Killer ANDREW J. DANNENBERG, M.D. November 17, 2017. Obesity and Breast Cancer • Risk factor for development of hormone receptor-

Breast Adipose Inflammation: a Silent Killer

ANDREW J. DANNENBERG, M.D.November 17, 2017

Page 2: Breast Adipose Inflammation: a Silent Killer · Silent Killer ANDREW J. DANNENBERG, M.D. November 17, 2017. Obesity and Breast Cancer • Risk factor for development of hormone receptor-

Obesity and Breast Cancer

• Risk factor for development of hormone receptor-positive breast cancer in postmenopausal women.

• Poor prognostic factor for breast cancer patients.

Page 3: Breast Adipose Inflammation: a Silent Killer · Silent Killer ANDREW J. DANNENBERG, M.D. November 17, 2017. Obesity and Breast Cancer • Risk factor for development of hormone receptor-

Pathways Linking Obesity with Breast Cancer

Sinicrope FA & Dannenberg AJ. J Clin Oncol 2011

Page 4: Breast Adipose Inflammation: a Silent Killer · Silent Killer ANDREW J. DANNENBERG, M.D. November 17, 2017. Obesity and Breast Cancer • Risk factor for development of hormone receptor-

Obesity Causes An Inflammatory State

Adapted from Olefsky & Glass. Annu. Rev. Physiol. 2010

Page 5: Breast Adipose Inflammation: a Silent Killer · Silent Killer ANDREW J. DANNENBERG, M.D. November 17, 2017. Obesity and Breast Cancer • Risk factor for development of hormone receptor-

Objective

• To determine if CLS of the breast (CLS-B) exist in women and correlate with BMI.

Page 6: Breast Adipose Inflammation: a Silent Killer · Silent Killer ANDREW J. DANNENBERG, M.D. November 17, 2017. Obesity and Breast Cancer • Risk factor for development of hormone receptor-

Study Design

• Breast tissue was obtained from women who underwent mastectomy.

• Routine H&E staining and CD68 IHC was performed.

Page 7: Breast Adipose Inflammation: a Silent Killer · Silent Killer ANDREW J. DANNENBERG, M.D. November 17, 2017. Obesity and Breast Cancer • Risk factor for development of hormone receptor-

CLS-B are Common in the Breasts of Overweight and Obese Women

CD68 stain

H&E stain

Iyengar et al. Cancer Prev Res 2015Morris PG et al. Cancer Prev Res 2011

Page 8: Breast Adipose Inflammation: a Silent Killer · Silent Killer ANDREW J. DANNENBERG, M.D. November 17, 2017. Obesity and Breast Cancer • Risk factor for development of hormone receptor-

Adipocyte Size Correlates with BMI and CLS-B Status

Iyengar et al. Cancer Prev Res 2015

Page 9: Breast Adipose Inflammation: a Silent Killer · Silent Killer ANDREW J. DANNENBERG, M.D. November 17, 2017. Obesity and Breast Cancer • Risk factor for development of hormone receptor-

Objective

• To determine whether breast white adipose tissue inflammation (WATi) manifested as CLS-B is associated with shortened recurrence free survival in women who develop metastatic breast cancer.

Page 10: Breast Adipose Inflammation: a Silent Killer · Silent Killer ANDREW J. DANNENBERG, M.D. November 17, 2017. Obesity and Breast Cancer • Risk factor for development of hormone receptor-

Clinicopathologic Characteristics in Patients with Recurrent Breast Cancer

Page 11: Breast Adipose Inflammation: a Silent Killer · Silent Killer ANDREW J. DANNENBERG, M.D. November 17, 2017. Obesity and Breast Cancer • Risk factor for development of hormone receptor-

CLS-B and Distant Recurrence-free Survival

*adjusted for age, race, BMI, breast cancer subtype, grade, T stage, N stage, hyperlipidemia, hypertension, DM, NeoadjChemo, AdjChemo, AdjEndo, AdjTrast, AdjRT.

Iyengar NM et al. Clin. Cancer Res. 2016

Page 12: Breast Adipose Inflammation: a Silent Killer · Silent Killer ANDREW J. DANNENBERG, M.D. November 17, 2017. Obesity and Breast Cancer • Risk factor for development of hormone receptor-

Conclusions

• Breast WAT inflammation is a/w metabolic syndrome.

• In patients who develop metastasis, WAT inflammation is associated with shortened distant recurrence free survival.

• Whether WAT inflammation promotes the progression of breast cancer via local effects, systemic mechanisms, e.g., hyperinsulinemia or both is uncertain.

Page 13: Breast Adipose Inflammation: a Silent Killer · Silent Killer ANDREW J. DANNENBERG, M.D. November 17, 2017. Obesity and Breast Cancer • Risk factor for development of hormone receptor-

Is WATi a/w Local or Systemic Effects that Promote Breast Cancer?

• Assess CLS-B status in 100 women with varying BMI

• RNA-seq on nontumorous breast tissue

• Fasting serum/plasma used to quantify:

- hsCRP, IL-6, insulin, glucose

Page 14: Breast Adipose Inflammation: a Silent Killer · Silent Killer ANDREW J. DANNENBERG, M.D. November 17, 2017. Obesity and Breast Cancer • Risk factor for development of hormone receptor-

Patient Characteristics by CLS-B Status

Page 15: Breast Adipose Inflammation: a Silent Killer · Silent Killer ANDREW J. DANNENBERG, M.D. November 17, 2017. Obesity and Breast Cancer • Risk factor for development of hormone receptor-

Breast WATi is a/w Elevated hsCRP, IL-6, Insulin and Glucose

Page 16: Breast Adipose Inflammation: a Silent Killer · Silent Killer ANDREW J. DANNENBERG, M.D. November 17, 2017. Obesity and Breast Cancer • Risk factor for development of hormone receptor-

Breast WAT Inflammation Occurs in Women with Normal BMI

Page 17: Breast Adipose Inflammation: a Silent Killer · Silent Killer ANDREW J. DANNENBERG, M.D. November 17, 2017. Obesity and Breast Cancer • Risk factor for development of hormone receptor-

WAT Inflammation is a/w Breast Adipocyte Hypertrophy in Normal BMI Women

Page 18: Breast Adipose Inflammation: a Silent Killer · Silent Killer ANDREW J. DANNENBERG, M.D. November 17, 2017. Obesity and Breast Cancer • Risk factor for development of hormone receptor-

Aromatase and the Local Production of Estrogens

aromatase

androgens

estrogens (incl. E2)

From Kristy Brown

Page 19: Breast Adipose Inflammation: a Silent Killer · Silent Killer ANDREW J. DANNENBERG, M.D. November 17, 2017. Obesity and Breast Cancer • Risk factor for development of hormone receptor-

Aromatase Protein Levels and Activity are Increased in the Inflamed Breast Tissue of Normal Sized Women

Iyengar NM et al. Cancer Prev Res 2017

Page 20: Breast Adipose Inflammation: a Silent Killer · Silent Killer ANDREW J. DANNENBERG, M.D. November 17, 2017. Obesity and Breast Cancer • Risk factor for development of hormone receptor-
Page 21: Breast Adipose Inflammation: a Silent Killer · Silent Killer ANDREW J. DANNENBERG, M.D. November 17, 2017. Obesity and Breast Cancer • Risk factor for development of hormone receptor-

Blood Variables Stratified by Inflammation

* P-values were obtained using linear regression adjusted for potential cohort differences.† Log-transformed data were used to ensure the underlying model assumptions were met.

Iyengar NM et al. Cancer Prev Res 2017

Page 22: Breast Adipose Inflammation: a Silent Killer · Silent Killer ANDREW J. DANNENBERG, M.D. November 17, 2017. Obesity and Breast Cancer • Risk factor for development of hormone receptor-

Elevated Insulin Levels Are a/w Increased Breast Cancer Risk in Normal Weight Women

Gunter MJ et al. Cancer Res. 2015

Page 23: Breast Adipose Inflammation: a Silent Killer · Silent Killer ANDREW J. DANNENBERG, M.D. November 17, 2017. Obesity and Breast Cancer • Risk factor for development of hormone receptor-

Conclusions

• WATi is a/w numerous changes in gene expression in the breast.

• WATi is a/w systemic changes that occur in the metabolic syndrome.

• WATi and its associated pathophysiology occur in a significant subset of normal BMI women.

• WATi is a potentially targetable process linking obesity to breast cancer.

Page 24: Breast Adipose Inflammation: a Silent Killer · Silent Killer ANDREW J. DANNENBERG, M.D. November 17, 2017. Obesity and Breast Cancer • Risk factor for development of hormone receptor-

CONTRIBUTORS Weill Cornell • Kotha Subbaramaiah, PhD• Xi Kathy Zhou, PhD• Priya Bhardwaj, BA • Baoheng Du, MD• Domenick Falcone, PhD• Louise Howe, PhD• Kristy Brown, PhD• Nils Wendel, BS

McGill • Michael Pollak, MD

Funding• NIH/NCI• The Breast Cancer Research

Foundation• Prevent Cancer Foundation

MSKCC• Clifford Hudis, MD• Neil Iyengar, MD• Patrick Morris, MD• Monica Morrow, MD• Dilip Giri, MD• Ayca Gucalp, MD